News

AC Immune is launching a Phase 1b/2a clinical trial to evaluate an investigational anti-tau vaccine called ACI-35.030 as a potential disease-modifying treatment for Alzheimer’s disease and other disorders characterized by the accumulation of tau protein. The presence of abnormal aggregates of beta-amyloid and tau proteins in the brain…

To foster the cognitive stimulation of its Alzheimer’s disease (AD) residents, an Arkansas senior living center collaborated with the University of Arkansas – Fort Smith (UAFS) to produce recreational 3D-printed items. A set of large-scale, lightweight, and colorful plastic nuts and bolts were made especially for those…

AZTherapies has completed enrollment for its Phase 3 COGNITE trial, testing the safety and efficacy of its investigational ALZT-OP1 for the treatment of early Alzheimer’s disease (AD). A total of 620 participants were enrolled following the screening of 1,800 patients, the company said. “With the COGNITE trial…

  A mutation in a gene linked to familial Alzheimer’s disease promotes the disease by reducing the points of contact between nerve cells and impairing neuronal communication, a study has found. A chemical compound, called EVP4593, partially rescued the mutation’s negative effects, suggesting it may hold a potential therapeutic…

The University of California, Berkeley (UC Berkeley) will receive an expected $47 million in a federal grant that will add advanced brain imaging to a pivotal study to determine whether lifestyle modifications can protect memory in those at risk of developing dementia. With the five-year grant from the…

Biopharmaceutical company Longeveron will use a $3 million Alzheimer’s Association grant to advance innovative research that uses adult stem cells to target neuroinflammation in people with mild Alzheimer’s disease (AD). Funding is through the organization’s Part the Cloud global research grant program, designed to find promising targets…

Alzheimer’s disease patients carrying a gene found only in humans, called CHRFAM7A, are less responsive to cholinesterase inhibitors, a new study reports. These findings may explain why some therapeutic benefits seen in animal studies have failed to translate to patients. Kinga Szigeti, MD, PhD,  director of the University…

Following the approval of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), Samus Therapeutics is launching a Phase 1 trial in the United States to evaluate the safety of its investigational therapy PU-AD, an epichaperome inhibitor, for the treatment of Alzheimer’s…

The small molecule inhibitor SM07883, being developed by Samumed, can effectively prevent tau protein toxic accumulation, and tau-mediated neuroinflammation in mice, data from preclinical studies show. As tau-associated mechanisms are implicated in Alzheimer’s disease, these findings suggest that SM07883 may represent a new strategy for the…

Having close relatives with Alzheimer’s disease is linked to poorer memory, a new study has found. The study, titled “Family history of Alzheimer’s disease alters cognition and is modified by medical and genetic factors,” was published in eLIFE. Having a family history of Alzheimer’s disease and…